VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study

A. Levis, A. P. Anselmo, A. Ambrosetti, F. Adamo, M. Bertini, E. Cavalieri, P. Gavarotti, A. Genua, M. Liberati, V. Pavone, D. Pietrasanta, M. M. Ricetti, D. R. Scalabrini, F. Salvi, U. Vitolo, E. Angelucci, M. Boccadoro, E. Gallo, F. Mandelli

Research output: Contribution to journalArticle

Abstract

Background: In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low incidence of HL in the elderly, prospective studies are lacking and the best treatment strategy is difficult to define. Patients and methods: One-hundred and five HL patients over 65 years of age were treated homogeneously with an original reduced-intensity regimen designed for HL in the elderly containing vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin (VEPEMB). Forty-eight early stage (IA-IIA) patients received three courses of VEPEMB followed by involved field irradiation. Fifty-seven advanced stage (IIB-IV) patients received six courses followed by radiotherapy limited to the areas of bulky disease. Results: Mean age was 71 years (range 66-83). Co-morbidities were present in 39 patients (37%). A treatment plan modification for poor tolerance or toxicity was needed in 18 patients. Results were satisfactory, even if they were better in early rather than in advanced stage disease: complete response rate 98% versus 58% (P

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalAnnals of Oncology
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2004

Keywords

  • Chemotherapy
  • Co-morbidity
  • Elderly
  • Hodgkin's lymphoma
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study'. Together they form a unique fingerprint.

Cite this